OpenNashEarnings

Pharmaceuticals · NYSE: PFE

Pfizer earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 2 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Pfizer reported third-quarter 2026 Revenues of $16.6 Billion, Reported Diluted EPS of $0.56 and Adjusted Diluted EPS of $0.87, and raised full-year 2026 guidance.

Pfizer's third-quarter 2026 revenue was $16.6 billion, relatively flat year over year. Revenue excluding Comirnaty and Paxlovid grew 7% operationally, and launched and acquired products grew 32%. Eliquis, Padcev and Nurtec rose, while Paxlovid, Comirnaty and Prevnar fell. Reported diluted EPS was $0.56 and adjusted diluted EPS was $0.87. Adjusted EPS includes about $0.10 of cost from the Innovent licensing charge.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗Official transcript (PDF) ↗

Quarters

KPI history

Revenue$16.6B−0.4% y/yQ3 2026
Q4 2024: $17.8B (worked out from the annual figure)Q4 ’24$17.8BQ1 2025: $13.7BQ1 ’25$13.7BQ2 2025: $14.7BQ2 ’25$14.7BQ3 2025: $16.7BQ3 ’25$16.7BQ4 2025: $17.6B (worked out from the annual figure)Q4 ’25$17.6BQ1 2026: $14.5BQ1 ’26$14.5BQ2 2026: $15.0BQ2 ’26$15.0BQ3 2026: $16.6BQ3 ’26$16.6B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$17.8B *
Q1 2025$13.7B
Q2 2025$14.7B
Q3 2025$16.7B
Q4 2025$17.6B *
Q1 2026$14.5B
Q2 2026$15.0B
Q3 2026$16.6B
Diluted EPS (GAAP)$0.56−9.7% y/yQ3 2026
Q1 2025: $0.52Q1 ’25$0.52Q2 2025: $0.51Q2 ’25$0.51Q3 2025: $0.62Q3 ’25$0.62Q1 2026: $0.47Q1 ’26$0.47Q2 2026: -$0.04Q2 ’26-$0.04Q3 2026: $0.56Q3 ’26$0.56
Data
Q1 2025$0.52
Q2 2025$0.51
Q3 2025$0.62
Q1 2026$0.47
Q2 2026-$0.04
Q3 2026$0.56

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Free cash flow$4.8B+20.0% y/yQ3 2026
Q4 2024: $5.8BQ4 ’24$5.8BQ1 2025: $1.8BQ1 ’25$1.8BQ2 2025: -$1.2BQ2 ’25-$1.2BQ3 2025: $4.0BQ3 ’25$4.0BQ4 2025: $4.5BQ4 ’25$4.5BQ1 2026: $2.2BQ1 ’26$2.2BQ2 2026: $302.0MQ2 ’26$302.0MQ3 2026: $4.8BQ3 ’26$4.8B
Data
Q4 2024$5.8B
Q1 2025$1.8B
Q2 2025-$1.2B
Q3 2025$4.0B
Q4 2025$4.5B
Q1 2026$2.2B
Q2 2026$302.0M
Q3 2026$4.8B

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$17.8Bd$13.7B$14.7B$16.7B$17.6Bd$14.5B$15.0B$16.6B
Net income$410.0Md$3.0B$2.9B$3.5B-$1.6Bd$2.7B-$248.0M$3.2B
Diluted EPS—$0.52$0.51$0.62—$0.47-$0.04$0.56
Operating cash flow$6.7Bd$2.3B-$582.0Md$4.6Bd$5.3Bd$2.6B$835.0Md$5.4Bd
Capital expenditure$917.0Md$564.0M$618.0Md$602.0Md$845.0Md$436.0M$533.0Md$573.0Md
Free cash flow$5.8B$1.8B-$1.2B$4.0B$4.5B$2.2B$302.0M$4.8B
R&D expense$3.0Bd$2.2B$2.5B$2.5B$3.2Bd$2.5B$2.8B$3.0B

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-Q and 10-K filings